Research News
View articles by month and year
-
Avastin Doesn’t Improve Survival in Metastatic Breast Cancer
The FDA is considering whether to continue the approval for using Avastin with Taxol to treat metastatic breast cancer, as well as whether to approve it in combination with other medicines.
-
Olaparib May Help Treat Triple-Negative Breast Cancer
Research suggests that combining the experimental targeted therapy olaparib with a taxane chemotherapy may be effective against triple-negative breast cancer.
-
HER2-Positive Breast Cancer May Respond to Experimental Treatments
Early results from a very early study suggests that some advanced-stage, HER2-positive breast cancers that have stopped responding to Herceptin may respond to the experimental treatment T-DM1.
-
Adding Avastin to Chemo Stops Metastatic Cancer From Growing
Adding Avastin to any of several common chemotherapy regimens for metastatic, HER2-negative breast cancer seems to lengthen the time before the cancer grows compared to the same regimen without Avastin.
-
Afinitor May Make Metastatic Breast Cancer Start Responding to Other Medicines Again
A small, early study suggests that Afinitor, a targeted therapy medicine, can make HER2-positive, metastatic breast cancers that have stopped responding to Herceptin and Taxol start responding to those treatments again.
-
Experimental Combo Shows Promise for Treating Metastatic HER2-Positive Cancer
A very small, very early study suggests that a combination of Herceptin and Afinitor may help treat HER2-positive, metastatic breast cancers that have stopped responding to many other treatments.
-
Retesting Metastatic Cancer’s HER2 Status Can Predict Response to Experimental Medicine
Retesting metastatic breast cancer for HER2 status -- to see if the cancer is still HER2-positive -- can help figure out if the cancer is more or less likely to respond to T-DM1, an experimental targeted therapy medicine.
-
Experimental Treatment for HER2-Positive Cancers Shows Promise
Several small, early research studies reviewed here suggest that an experimental targeted therapy medicine, neratinib, may be able to treat HER2-positive, advanced-stage breast cancers some day.
-
Experimental Regimen May Work Against Treatment-Resistant Breast Cancer
A combination of two experimental targeted therapies shows promise in treating advanced-stage HER2-positive breast cancer.
-
Radioactive Tag on Herceptin May Allow Doctors to Track Effectiveness
Attaching a radioactive tag to the targeted therapy Herceptin might allow researchers to monitor how HER2-positive breast cancer cells respond to Herceptin treatment.
